menu
    • menu

    Company profile for Azura Ophthalmics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Azura Ophthalmics is taking a unique approach to the treatment of ocular surface disease (OSD). Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as Meibomian gland dysfunction (MGD), Blepharitis and Contact Lens Discomfort. Because Meibomian glands in the eyelids are similar to the hair fol...
    Azura Ophthalmics is taking a unique approach to the treatment of ocular surface disease (OSD). Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as Meibomian gland dysfunction (MGD), Blepharitis and Contact Lens Discomfort. Because Meibomian glands in the eyelids are similar to the hair follicles and sebaceous (oil-producing) glands of the skin1, our approach combines ophthalmologic and dermatologic strategies to develop effective treatments for MGD and related conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Azura OphthalmicsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    5 Druyanov Street Tel Aviv 6314305
    Telephone
    Telephone
    +972 3 647 5312
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://azuraophthalmics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/azura-ophthalmics-limited
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Azura Ophthalmics: First Patient In Phase 3 MGD Trial For AZR-MD-001
    Azura Ophthalmics: First Patient In Phase 3 MGD Trial For AZR-MD-001

    04 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240604057488/en

    BUSINESSWIRE
    04 Jun 2024
    Share Share
    Azura Ophthalmics to Present Data of AZR-MD-001 for Ocular Surface Diseases
    Azura Ophthalmics to Present Data of AZR-MD-001 for Ocular Surface Diseases

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328891425/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    Azura Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001
    Azura Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001

    18 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231218472244/en

    BUSINESSWIRE
    18 Dec 2023
    Share Share
    Azura Ophthalmics to Present New Data on AZR-MD-001 Gland Dysfunction
    Azura Ophthalmics to Present New Data on AZR-MD-001 Gland Dysfunction

    20 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230420005240/en

    BUSINESSWIRE
    20 Apr 2023
    Share Share
    Azura Ophthalmics Announces Participation at the 2023 SVB Conference
    Azura Ophthalmics Announces Participation at the 2023 SVB Conference

    17 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230117005976/en

    BUSINESSWIRE
    17 Jan 2023
    Share Share
    Azura Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001
    Azura Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001

    09 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221209005090/en

    BUSINESSWIRE
    09 Dec 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search